This week there has been a great deal of (political) discussion about imposing constraints on the pricing of new drugs, particularly orphan drugs. Artificial price constraints could distrupt your model. Could the model sustain such restraints?
Moving from a blockbuster to an orphan drug model, you noted that fewer patients will be eligible for treatment, which may not good for drug developers. But why would drug prices not increase a lot to account for the better matching of drug to patients?
Your approach to relaxing the current financial constraint will only succeed if there exists an unending stream of good ideas to cure cancer that now remain unfunded. Do you believe that to be the case?
I thought Langers "horizon" issue was a big point - aligning short term vs long term horizon on the outcome is important. Lo thinks there is room and economic oppty for new therapeutic
